A Phase I Study of Stereotactic Body Radiation Therapy for Inoperable Locally Advanced Non-Small Cell Lung Cancer

Protocol
13-113
Full Title
Stereotactic Body Radiation Therapy for Inoperable Locally-Advanced Non-Small Cell Lung Cancer
Phase
I
Disease Status
Newly Diagnosed
Purpose

Stereotactic body radiation therapy (SBRT) involves giving higher individual doses of radiation over fewer days as compared to standard radiation therapy. It has been very effective in the treatment of small lung lesions and is now the standard of care for inoperable early-stage NSCLC.

Doctors are interested in seeing if SBRT could also be useful to treat patients with larger (locally advanced) NSCLC when given with chemotherapy. In this study, researchers are determining the highest dose of SBRT (doses of at least 40 Gy and up to 60 Gy) that can be given safely to patients with inoperable locally advanced NSCLC.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have locally advanced (stage IIA to IIIA) NSCLC that cannot be surgically removed and has not yet been treated with chemotherapy or radiation therapy.
  • Patients should be eligible for cisplatin- or carboplatin-based chemotherapy.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Andreas Rimner at 212-639-6025.

Disease(s)
Lung Cancer, Non-Small Cell